Brii Biosciences Limited (2137) AI Stock Analysis

• Market Cap: HK$1.09B
• Dividend Yield: N/A
• Average Volume (3M): 6.36M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: N/A
• EPS Growth: -41.48%
• Country: HK
• Employees: 98
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 733,900,600
• 10 Day Avg. Volume: 5,897,564
• 30 Day Avg. Volume: 6,360,478
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.25
• Price to Sales (P/S): 12.38
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: HK$1.50 ▲(4.17% Upside)

Brii Biosciences' overall stock score is primarily impacted by its financial performance and technical analysis. The company's profitability and cash flow challenges, coupled with bearish technical indicators, significantly weigh down the score. The negative P/E ratio further contributes to a low valuation score.

Positive Factors

Therapeutic Focus & Platform

Brii’s strategic focus on viral infections and antimicrobial resistance, supported by proprietary technology platforms, positions it in structurally important healthcare areas with persistent unmet need. This specialization supports durable R&D prioritization and potential long-term market relevance if clinical progress continues.

Partnership-Driven Revenue Model

A revenue model tied to collaborations, milestones and royalties provides diversified, potentially non-dilutive funding for development. Long-term this can de-risk runway and financing needs, aligning incentives with larger pharma partners and facilitating global commercialization through established networks.

Strong Equity & Cash Buffer

Reported strong equity and sizable cash reserves give the company a material financial buffer against near-term cash burn. This strengthens the ability to fund R&D and regulatory programs over multiple quarters, preserving strategic optionality and reducing immediate refinancing pressure.

Negative Factors

Persistent Negative Free Cash Flow

Ongoing negative free cash flow and absent operating cash generation in 2024 indicate the business currently consumes cash to fund operations. Over months this raises reliance on external financing, which can dilute shareholders or constrain investment timing, risking delays to clinical and commercial milestones.

Widening Net Loss & Revenue Decline

A revenue decline alongside a materially wider net loss signals deteriorating commercial or operational performance. Structurally, persistent losses can erode flexibility to invest in high-return programs, pressure margins, and necessitate strategic pivots or cost cutting that could slow long-term growth trajectories.

Historical Negative Equity & Leverage Concerns

Past negative equity and a concerning debt-to-equity ratio reflect legacy balance-sheet stress that can constrain access to favorable financing and increase cost of capital. Structurally this limits strategic flexibility, may impose covenant risk, and can impact partner or investor confidence over the medium term.

Brii Biosciences Limited Business Overview & Revenue Model

Company Description

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

How the Company Makes Money

Brii Biosciences generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from partnerships and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. The company may also receive funding through government grants or research initiatives aimed at combating infectious diseases. Additionally, successful clinical trials and regulatory approvals can lead to significant revenue opportunities through product launches in various markets. Strategic collaborations with healthcare organizations and institutions further enhance its revenue potential, enabling broader access to its innovative therapies.

Brii Biosciences Limited Financial Statement Overview

Summary

Brii Biosciences faces significant profitability and cash flow challenges, with a widening net loss and consistent negative free cash flow. Despite strong equity and substantial cash reserves, these issues pose threats to financial stability.

Income Statement

Brii Biosciences has experienced fluctuating revenue trends with a decline from 2023 to 2024. The net loss widened significantly in 2024, indicating profitability challenges. Margins such as the Gross Profit Margin remain stable at 100%, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company's balance sheet shows a strong equity position but also reveals a concerning debt-to-equity ratio due to negative equity in previous years. The equity ratio is favorable, indicating a well-capitalized company, though historical liabilities have been significant relative to assets.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which suggests challenges in generating cash from operations. The lack of operating cash flow in 2024 highlights potential liquidity risks, though substantial cash reserves provide a buffer.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.12M	54.29M	56.32M	51.63M	92.54M	82.22M
Gross Profit	33.12M	54.29M	56.32M	51.63M	92.54M	82.22M
EBITDA	-352.36M	-392.51M	-168.20M	-503.58M	-602.80M	-890.79M
Net Income	-375.69M	-508.16M	-174.83M	-484.31M	-4.12B	-1.21B
Balance Sheet
Total Assets	2.49B	2.71B	3.20B	3.39B	3.61B	1.27B
Cash, Cash Equivalents and Short-Term Investments	2.07B	2.33B	2.66B	3.00B	3.35B	1.05B
Total Debt	7.39M	28.02M	3.16M	12.66M	21.62M	28.33M
Total Liabilities	51.48M	100.55M	125.87M	234.35M	300.44M	3.01B
Stockholders Equity	2.49B	2.66B	3.12B	3.19B	3.34B	-1.74B
Cash Flow
Free Cash Flow	-149.56M	-376.12M	-643.62M	-635.57M	-880.49M	-403.72M
Operating Cash Flow	-147.10M	-372.89M	-594.01M	-496.28M	-879.46M	-403.72M
Investing Cash Flow	501.56M	895.47M	-104.35M	-1.43B	-475.76M	-43.65M
Financing Cash Flow	-4.98M	-9.41M	-10.98M	-3.04M	3.23B	657.00M

Brii Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Negative. The current price of 1.44 is below the 20-day moving average (MA) of 1.55, below the 50-day MA of 1.57, and below the 200-day MA of 1.83, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 51.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2137.

Brii Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	60 Neutral	HK$3.18B	392.38	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6998	48 Neutral	HK$5.02B	56.31	2.04%	―	1447.56%	―
2511	46 Neutral	HK$1.36B	-3.85	-67.27%	―	―	47.42%
2137	43 Neutral	HK$1.09B	-2.71	-14.48%	―	―	-41.48%
1244	41 Neutral	HK$1.23B	-6.40	-21.45%	―	-8.43%	64.33%
2126	41 Neutral	HK$1.01B	-1.48	-51.56%	―	2.45%	2.58%

Brii Biosciences Limited Corporate Events

Brii Biosciences Updates Nomination Committee Terms

Brii Biosciences Limited has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. The committee’s structure and operational guidelines emphasize diversity and independence, aiming to enhance the board’s performance and governance, reflecting the company’s commitment to robust corporate governance practices.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Reports Promising Results from Phase 2 HBV Study

Brii Biosciences Limited has announced promising 24-week post-treatment follow-up results from Cohort 4 of its Phase 2 ENSURE study, presented at the AASLD 2025. The study evaluates a novel treatment strategy for HBV using the company’s therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFN α. The results indicate a sustained hepatitis B surface antigen (HBsAg) loss in patients who responded to BRII-179, suggesting its potential to improve functional cure outcomes. This development could enhance the company’s position in the HBV treatment market and offer new hope for diverse patient populations.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences’ Phase 2 Study Shows Promise in Hepatitis B Treatment

Brii Biosciences Limited announced the publication of its Phase 2 ENSURE study results in Nature Medicine, highlighting the efficacy and safety of elebsiran combined with pegylated interferon alfa (PEG-IFN α) for chronic hepatitis B treatment. The study demonstrated that the combination therapy resulted in higher hepatitis B surface antigen (HBsAg) loss rates compared to PEG-IFN α monotherapy, particularly among patients responsive to the BRII-179 vaccine. These findings suggest a promising role for BRII-179 in enhancing immune response and expanding treatment eligibility, potentially positioning Brii Biosciences as a leader in hepatitis B curative therapies.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.